James H. Doroshow, MD, of the National Cancer Institute, describes a new precision medicine initiative called the MATCH trial: Molecular Analysis for Therapy Choice. In 2,400 NCI clinical trial sites, 3,000 patients will be screened and their tumors analyzed to determine whether they contain genetic abnormalities for which a targeted drug exists.
James O. Armitage, MD, of the University of Nebraska Medical Center, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss oncology from an international point of view.
James O. Armitage, MD, of the University of Nebraska Medical Center, and Asher Alban Akmal Chanan-Khan, MD, of the Mayo Clinic Cancer Center, discuss an important treatment option that significantly improved overall response rate and reduced risk of progression or death by 80% (Abstract LBA7005).
Richard G. Margolese, MD, of McGill University discusses the improvement in breast cancer-free interval with anastrozole vs tamoxifen in patients with DCIS undergoing lumpectomy plus radiotherapy (Abstract LBA500).
Jan C. Buckner, MD, of the Mayo Clinic discusses adjuvant whole-brain radiotherapy and the need for initial treatment with radiosurgery and close monitoring to preserve cognitive function in patients with brain metastases (Abstract LBA4).
Thomas W. LeBlanc, MD, of Duke University Medical Center, and Eric Roeland, MD, FAAHPM, of the University of California, San Diego Moores Cancer Center, discuss the use of palliative and hospice care for patients with solid tumors vs hematologic cancers and clinicians’ attitudes (Abstracts e20554 and 9524).
